Crescent Biopharma (NASDAQ:CBIO – Get Free Report) and BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.
Profitability
This table compares Crescent Biopharma and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Crescent Biopharma | N/A | -125.38% | -104.16% |
| BioCryst Pharmaceuticals | 30.16% | -84.33% | 61.35% |
Institutional and Insider Ownership
75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 8.7% of Crescent Biopharma shares are held by company insiders. Comparatively, 5.1% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Crescent Biopharma | 1 | 0 | 5 | 3 | 3.11 |
| BioCryst Pharmaceuticals | 0 | 3 | 10 | 0 | 2.77 |
Crescent Biopharma currently has a consensus target price of $28.00, indicating a potential upside of 43.44%. BioCryst Pharmaceuticals has a consensus target price of $19.64, indicating a potential upside of 103.06%. Given BioCryst Pharmaceuticals’ higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Crescent Biopharma.
Earnings & Valuation
This table compares Crescent Biopharma and BioCryst Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Crescent Biopharma | $10.84 million | 25.01 | -$153.94 million | ($14.21) | -1.37 |
| BioCryst Pharmaceuticals | $874.84 million | 2.77 | $263.86 million | $1.20 | 8.06 |
BioCryst Pharmaceuticals has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Crescent Biopharma has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.
Summary
BioCryst Pharmaceuticals beats Crescent Biopharma on 10 of the 15 factors compared between the two stocks.
About Crescent Biopharma
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Crescent Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
